SeaBeLife Biotech

SeaBeLife Biotech is pioneering a novel therapeutic approach by developing dual inhibitors of regulated necrosis pathways (necroptosis and ferroptosis), a mechanism implicated in a wide range of severe organ diseases. Its most advanced program, SBL03, is a topical ophthalmic gel for geographic atrophy (GA) in dry AMD, which has shown promising preclinical efficacy and secured an Orphan Drug Designation from the EMA. The company is privately held, pre-revenue, and operates with a capital-efficient model through strategic partnerships, such as its joint development agreement with Unither Pharmaceuticals, to advance its pipeline from preclinical to clinical stages.

Patented small molecule platform designed to simultaneously inhibit two forms of regulated cell death (necroptosis and ferroptosis) to provide cytoprotection in acute and degenerative organ diseases.

In dry AMD, SeaBeLife faces competition from recently approved complement inhibitors (Syfovre, Izervay) and other late-stage therapies, though its topical route of administration is a key point of differentiation. In regulated cell death inhibition, it competes with companies developing single-pathway inhibitors of necroptosis or ferroptosis (e.g., for neurodegenerative diseases), but claims a unique position with its dual-target approach. For acute hepatitis, there are currently no direct pharmacologic competitors, positioning it as a potential first mover.